Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 428

1.

Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumor Cells.

Herrera-Martínez AD, Feelders RA, de Herder WW, Castaño JP, Gálvez Moreno MÁ, Dogan F, van Dungen R, van Koetsveld P, Hofland LJ.

Horm Cancer. 2019 Jun;10(2-3):107-119. doi: 10.1007/s12672-019-00361-6. Epub 2019 May 18.

PMID:
31102172
2.

Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE.

Zandee WT, Feelders RA, Smit Duijzentkunst D, Hofland J, Metselaar RM, Oldenburg RA, van Linge A, Kam BLR, Teunissen J, Korpershoek E, Hendriks J, Abusaris H, Slagter C, Franssen GJH, Brabander T, de Herder W.

Eur J Endocrinol. 2019 May 1. pii: EJE-18-0901.R1. doi: 10.1530/EJE-18-0901. [Epub ahead of print]

PMID:
31067510
3.

Turning up the heat: Endoscopic Ablation of Pancreatic Neuroendocrine Neoplasms.

Hofland J, de Herder WW, Kann PH.

J Clin Endocrinol Metab. 2019 May 6. pii: jc.2019-00954. doi: 10.1210/jc.2019-00954. [Epub ahead of print] No abstract available.

PMID:
31058975
4.

Letter to the editor: The Inflammation-Based Index Can Predict Response and Improve Patient Selection in NETs Treated With PRRT: A Pilot Study.

Hofland J, Brabander T, de Herder WW.

J Clin Endocrinol Metab. 2019 Apr 30. pii: jc.2019-00681. doi: 10.1210/jc.2019-00681. [Epub ahead of print] No abstract available.

PMID:
31038673
5.

Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls.

Beukhof CM, Brabander T, van Nederveen FH, van Velthuysen MF, de Rijke YB, Hofland LJ, Franssen GJH, Fröberg LAC, Kam BLR, Visser WE, de Herder WW, Peeters RP.

BMC Cancer. 2019 Apr 5;19(1):325. doi: 10.1186/s12885-019-5540-5.

6.

Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.

Herrera Martínez AD, van den Dungen R, Dogan F, van Koetsveld PM, Culler M, de Herder WW, Luque RM, Feelders RA, Hofland L.

Endocr Relat Cancer. 2019 Apr 1. pii: ERC-19-0086. doi: 10.1530/ERC-19-0086. [Epub ahead of print]

PMID:
30939452
7.

Response to Prof. Ingo Brink and Prof. Aubalewska-Dydejczyk regarding Their "Letter to the Editor".

Sundin A, Fanti S, Giammarile F, de Herder WW.

Neuroendocrinology. 2019;108(4):366. doi: 10.1159/000497419. Epub 2019 Mar 27. No abstract available.

PMID:
30917382
8.

IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer.

De Martino MC, van Koetsveld PM, Feelders RA, de Herder WW, Dogan F, Janssen JAMJL, Hofste Op Bruinink D, Pivonello C, Waaijers AM, Colao A, de Krijger RR, Pivonello R, Hofland LJ.

Endocrine. 2019 Jun;64(3):673-684. doi: 10.1007/s12020-019-01869-1. Epub 2019 Mar 5.

9.

MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer.

Creemers SG, van Koetsveld PM, de Herder WW, Dogan F, Franssen GJH, Feelders RA, Hofland L.

Endocr Relat Cancer. 2019 Jan 1. pii: ERC-18-0500.R1. doi: 10.1530/ERC-18-0500. [Epub ahead of print]

PMID:
30650062
10.

Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers.

Herrera-Martínez AD, Hofland LJ, Gálvez Moreno MA, Castaño JP, de Herder WW, Feelders RA.

Endocr Relat Cancer. 2019 Mar 1;26(3):R157-R179. doi: 10.1530/ERC-18-0354. Review.

PMID:
30615596
11.

Management of carcinoid syndrome: a systematic review and meta-analysis.

Hofland J, Herrera Martínez AD, Zandee WT, de Herder WW.

Endocr Relat Cancer. 2019 Jan 1. pii: ERC-18-0495.R1. doi: 10.1530/ERC-18-0495. [Epub ahead of print] Review.

PMID:
30608900
12.

Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.

Zandee WT, Brabander T, Blažević A, Kam BLR, Teunissen JJM, Feelders RA, Hofland J, de Herder WW.

J Clin Endocrinol Metab. 2019 Apr 1;104(4):1336-1344. doi: 10.1210/jc.2018-01991.

PMID:
30566620
13.

Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives.

Herrera-Martínez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Gálvez Moreno MA, Luque RM, Castaño JP, de Herder WW, Feelders RA.

Drugs. 2019 Jan;79(1):21-42. doi: 10.1007/s40265-018-1033-0. Review.

14.

Unmet Needs in the Field of Neuroendocrine Neoplasms of the Gastrointestinal Tract, Pancreas, and Respiratory System: Reports by the ENETS Group.

de Herder WW, Capdevila J.

Neuroendocrinology. 2019;108(1):5-6. doi: 10.1159/000495036. Epub 2018 Dec 5. No abstract available.

15.

Role of the tumor microenvironment in digestive neuroendocrine tumors

Cuny T, de Herder W, Barlier A, Hofland LJ.

Endocr Relat Cancer. 2018 Nov 1;25(11):R519-R544. doi: 10.1530/ERC-18-0025.

PMID:
30306777
16.

Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study.

Rindi G, Klersy C, Albarello L, Baudin E, Bianchi A, Buchler MW, Caplin M, Couvelard A, Cros J, de Herder WW, Delle Fave G, Doglioni C, Federspiel B, Fischer L, Fusai G, Gavazzi F, Hansen CP, Inzani F, Jann H, Komminoth P, Knigge UP, Landoni L, La Rosa S, Lawlor RT, Luong TV, Marinoni I, Panzuto F, Pape UF, Partelli S, Perren A, Rinzivillo M, Rubini C, Ruszniewski P, Scarpa A, Schmitt A, Schinzari G, Scoazec JY, Sessa F, Solcia E, Spaggiari P, Toumpanakis C, Vanoli A, Wiedenmann B, Zamboni G, Zandee WT, Zerbi A, Falconi M.

Neuroendocrinology. 2018;107(4):375-386. doi: 10.1159/000494355. Epub 2018 Oct 9.

17.

Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours.

van der Zwan WA, Brabander T, Kam BLR, Teunissen JJM, Feelders RA, Hofland J, Krenning EP, de Herder WW.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):704-717. doi: 10.1007/s00259-018-4158-1. Epub 2018 Sep 28.

18.

Role of biomarker tests for diagnosis of neuroendocrine tumours.

Hofland J, Zandee WT, de Herder WW.

Nat Rev Endocrinol. 2018 Nov;14(11):656-669. doi: 10.1038/s41574-018-0082-5. Review.

PMID:
30158549
19.

When and How to Use Somatostatin Analogues.

de Herder WW.

Endocrinol Metab Clin North Am. 2018 Sep;47(3):549-555. doi: 10.1016/j.ecl.2018.04.010. Epub 2018 Jul 11. Review.

PMID:
30098715
20.

Identifying Prognostic Factors for Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumours: A Retrospective International Multicentre Cohort Study.

Jiménez-Fonseca P, Krug S, Tamagno G, Fierro Maya F, Monléon Getino A, Rodriguez Casado CI, Costa F, de Herder WW, Jann H.

Neuroendocrinology. 2018;107(4):315-323. doi: 10.1159/000492223. Epub 2018 Jul 19.

PMID:
30025389

Supplemental Content

Loading ...
Support Center